Spots Global Cancer Trial Database for relapsed chronic lymphocytic leukemia
Every month we try and update this database with for relapsed chronic lymphocytic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00290004 | Chronic Lymphoc... Small Lymphocyt... Leukemia Lymphoma | motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | NCT05828589 | Relapsed Non-Ho... Refractory Non-... Relapsed Chroni... Refractory Chro... Relapsed Follic... Relapsed Margin... Relapse Diffuse... Relapsed Small ... Refractory Foll... Refractory Marg... Refractory Smal... Richter Transfo... Refractory Diff... Transformed Non... | BGB-21447 | 18 Years - | BeiGene | |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | NCT05828589 | Relapsed Non-Ho... Refractory Non-... Relapsed Chroni... Refractory Chro... Relapsed Follic... Relapsed Margin... Relapse Diffuse... Relapsed Small ... Refractory Foll... Refractory Marg... Refractory Smal... Richter Transfo... Refractory Diff... Transformed Non... | BGB-21447 | 18 Years - | BeiGene | |
| Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia | NCT05246345 | Chronic Lymphoc... CLL Progressive Chr... Refractory Chro... Relapsed Chroni... | 18 Years - | University Hospital, Clermont-Ferrand | ||
| A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) | NCT00076401 | Leukemia Leukemia, Lymph... | Motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab | NCT01123356 | Chronic Lymphoc... | Ofatumumab Lenalidomide | 18 Years - | Medical University of South Carolina | |
| Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00100711 | Chronic Lymphoc... Small Lymphocyt... | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL | NCT00330252 | Chronic Lymphoc... | Rituximab Alemtuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL | NCT01750567 | Relapsed Chroni... | Metformin | 18 Years - 80 Years | University of Michigan Rogel Cancer Center | |
| A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) | NCT00076401 | Leukemia Leukemia, Lymph... | Motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) | NCT00076401 | Leukemia Leukemia, Lymph... | Motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00290004 | Chronic Lymphoc... Small Lymphocyt... Leukemia Lymphoma | motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| Allo HSCT Using RIC and PTCy for Hematological Diseases | NCT05805605 | Acute Myelogeno... Acute Lymphocyt... Biphenotypic Ac... Undifferentiate... Prolymphocytic ... Chronic Myeloge... Plasma Cell Leu... Myelodysplastic... Leukemia, Myelo... Myelodysplastic... Burkitt Lymphom... Relapsed T-Cell... Relapsed Chroni... Small Lymphocyt... Marginal Zone L... Follicular Lymp... Myeloproliferat... Myelofibrosis | Peripheral Bloo... Allopurinol 300... Fludarabine Cyclophosphamid... Bone Marrow Cel... Total Body Irra... Sirolimus Pill Mycophenolate M... | - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Intra-Osseous Co-Transplant of UCB and hMSC | NCT02181478 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Myelofibrosis Relapsed Non-Ho... Refractory Non-... Hodgkin Lymphom... Refractory Hodg... Relapsed Chroni... Refractory Chro... Lymphoid Malign... Chronic Myeloge... | cyclophosphamid... fludarabine pho... total-body irra... cyclosporine mycophenolate m... umbilical cord ... mesenchymal ste... | 18 Years - 75 Years | Case Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
